Boswellic Acid — AKBA (Triterpene Acid · 5-LOX Inhibitor · Arthritis · Anti-inflammatory)
| Compound | Boswellic Acids (AKBA; 3-O-Acetyl-11-keto-β-boswellic acid) |
| Chemical class | Terpenoid — Triterpene Acid (Pentacyclic oleanane-type; multiple isomers) |
| CAS | 67416-61-9 (AKBA) |
| Primary source | Boswellia serrata (Indian frankincense, gum resin), B. sacra, B. carterii |
| Key applications | 5-LOX inhibitor; anti-inflammatory (arthritis, asthma, IBD, cancer); neuroprotective |
| Claim strength | High |
| Typical form | Boswellia extract standardised to 30–65% total boswellic acids; AKBA-enriched extracts (ApresFlex/Aflapin) |
| Buy from Herbuno |
Boswellia serrata (Indian Frankincense) Extract Powder | Shallaki → Liposomal Boswellia 20% Powder - Boswellia serrata | Shallaki → |
Name origin: From Boswellia (the genus; named after John Boswell, 18th-century Scottish botanist). Boswellic acids are a family of pentacyclic triterpene acids in Boswellia resin, with four primary bioactive forms: β-boswellic acid (β-BA), acetyl-β-boswellic acid (ABA), 11-keto-β-boswellic acid (KBA), and 3-O-acetyl-11-keto-β-boswellic acid (AKBA). AKBA is the most potent and pharmacologically studied boswellic acid. Traditional use: Frankincense (Boswellia resin — Olibanum, Shallaki in Ayurveda) has been used in religious ceremonies and as a medicinal resin for at least 5,000 years — across Indian, Arabic, Egyptian, and East African traditions — for inflammatory conditions, digestive disorders, and wound healing. Ayurvedic texts (Sushruta Samhita) document Boswellia for joint conditions. Pharmacology — 5-LOX inhibition: AKBA is a non-competitive, non-redox inhibitor of 5-lipoxygenase (5-LOX) — the enzyme converting arachidonic acid to leukotrienes (LTA4 → LTB4, cysteinyl leukotrienes). Leukotrienes are primary mediators of airway inflammation (asthma) and articular inflammation (arthritis). Unlike NSAIDs (which inhibit COX enzymes), boswellic acids specifically inhibit the leukotriene pathway, making them complementary to COX-targeted anti-inflammatories and particularly useful in leukotriene-driven conditions (asthma, IBD). Commercial source: Boswellia serrata extract powder and liposomal Boswellia 20% powder, plus water-soluble frankincense liquid extract is available from Herbuno.
Evidence for Boswellic Acid Applications
Osteoarthritis — knee pain (High evidence): Multiple RCTs of Boswellia extract (200–400 mg AKBA/day) for knee osteoarthritis demonstrate significant reduction in WOMAC pain scores, improved function, and reduced joint swelling versus placebo. A Cochrane-reviewed meta-analysis (2014) concluded strong evidence for Boswellia extract in osteoarthritis pain reduction. The ApresFlex/Aflapin formulations (enriched AKBA) show effects within 5–7 days — faster than most joint supplements. Claim strength: High.
Asthma — leukotriene-mediated airway inflammation: A landmark RCT (Gupta et al., 1998, Eur J Med Res) with 40 asthma patients found 70% of Boswellia-treated patients showed significant improvement in FEV1, symptoms, and blood eosinophil counts versus 27% in placebo. The leukotriene pathway specificity of AKBA is mechanistically consistent with asthma benefits. Claim strength: Moderate (limited RCTs; mechanistically strong).
Inflammatory bowel disease (IBD): Boswellia extract has been studied in Crohn’s disease and ulcerative colitis — RCTs show reductions in Crohn’s Disease Activity Index (CDAI) and improvement in histological parameters in UC. Leukotriene B4 (LTB4) is a primary mediator of intestinal inflammation in IBD; AKBA’s 5-LOX inhibition is directly mechanistically relevant. Claim strength: Moderate (multiple RCTs; smaller effect sizes than pharmaceutical IBD therapies).
Anticancer (AKBA — topoisomerase II and NF-κB): AKBA inhibits topoisomerase II (an enzyme essential for DNA replication) and suppresses NF-κB — two mechanisms relevant to cancer cell growth and survival. Preclinical data across prostate, breast, colon, and glioma cell lines are promising. No Phase II/III clinical oncology trials have been completed. Claim strength: Emerging.
Boswellia serrata (Indian Frankincense) Extract Powder | Shallaki →
Liposomal Boswellia 20% Powder - Boswellia serrata | Shallaki →
Browse Standardised Extract Powders →
Dosage & Formulator Specification
Standard Boswellia extract: 300–500 mg/day of extract standardised to 30–65% total boswellic acids (delivering 90–325 mg boswellic acids). For osteoarthritis RCTs: 100–250 mg AKBA/day (from ApresFlex/Aflapin-type enriched extract). AKBA has poor oral bioavailability due to low aqueous solubility — liposomal or phospholipid-complexed Boswellia (as in Herbuno’s Liposomal Boswellia 20%) significantly improves AKBA absorption (3–5× improvement in AUC). For arthritis applications, liposomal or enriched AKBA formulations are preferred over standard extracts. Specify total boswellic acid % AND AKBA % separately on CoA. Note: β-boswellic acid (the most abundant form in standard extracts) is a COX inhibitor, not a 5-LOX inhibitor — only AKBA and KBA are 5-LOX selective. Some poorly standardised extracts have high β-BA but low AKBA — verify AKBA content specifically.
Frequently Asked Questions — Boswellic Acids
Why is AKBA the most important boswellic acid?
AKBA (3-O-acetyl-11-keto-β-boswellic acid) is the most potent 5-LOX inhibitor among the boswellic acids (IC50 ~1.5 μM), compared to KBA (IC50 ~3 μM) and ABA (IC50 ~7 μM). The 11-keto group and 3-acetoxy group together confer optimal 5-LOX binding geometry. Additionally, AKBA inhibits cathepsin G (a serine protease in neutrophils) and HLE (human leukocyte elastase), providing anti-inflammatory breadth beyond 5-LOX. Commercial extracts that report only “total boswellic acids” without specifying AKBA content may have widely varying pharmacological potency.
Is Boswellia safe for long-term use?
Boswellia extract has an excellent safety profile in trials up to 12 months duration. The most common adverse effects are mild GI symptoms (nausea, diarrhoea) at higher doses — substantially less frequent than NSAIDs’ GI effects at equivalent anti-inflammatory efficacy doses. No hepatotoxicity, nephrotoxicity, or cardiovascular adverse events have been associated with Boswellia in clinical trials. It does not inhibit COX enzymes at therapeutic doses, so there is no platelet aggregation concern (unlike aspirin or NSAIDs). This safety profile supports long-term use in conditions like osteoarthritis and IBD where chronic anti-inflammatory therapy is required.
How does Boswellia compare to turmeric/curcumin for arthritis?
Both are botanically-derived anti-inflammatories with RCT support for arthritis. Curcumin inhibits COX-2, NF-κB, and multiple inflammatory targets; Boswellia (AKBA) primarily inhibits 5-LOX. Their mechanisms are complementary, not overlapping. Clinical head-to-head data show comparable pain reduction for each alone in osteoarthritis RCTs, with some combination studies suggesting additive benefit. For formulation, the Curcumin + Boswellia combination is one of the most evidence-supported botanical anti-inflammatory combinations available.
What is ApresFlex/Aflapin and how does it differ from standard Boswellia extract?
ApresFlex (IXOREAL Biomed) and Aflapin (Laila Nutraceuticals) are proprietary Boswellia formulations enriched in AKBA (typically 20–30% AKBA vs 3–5% in standard extracts) combined with non-volatile Boswellia oil fractions that improve AKBA absorption. Both have published RCTs showing superior bioavailability and faster onset of osteoarthritis symptom relief (7 days) versus standard extract. They are patented ingredients; generic AKBA-enriched Boswellia extracts without these specific proprietary formulation technologies may not replicate the clinical trial data exactly.
Related compounds: Curcumin, Parthenolide, Ursolic Acid, Lupeol
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery